Topics

Delcath Systems Inc DCTH Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $125

18:34 EDT 11 Oct 2019 | BioPortfolio Reports

Delcath Systems Inc DCTH Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.


The profile contains critical company information including:


Business description A detailed description of the company's operations and business divisions.

Corporate strategy Analyst's summarization of the company's business strategy.

SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history Progression of key events associated with the company.

Major products and services A list of major products, services and brands of the company.

Key competitors A list of key competitors to the company.

Key employees A list of the key executives of the company.

Executive biographies A brief summary of the executives' employment history.

Key operational heads A list of personnel heading key departments/functions.

Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Highlights


Delcath Systems Inc Delcath specializes in developing percutaneous perfusion technologies to treat primary and metastatic liver cancers. Its patented drug delivery platform delivers ultrahigh doses of anticancer drugs to the liver, while preventing them from entering the patient's bloodstream. The company develops formulations for use with its proprietary Delcath Hepatic Delivery System Melphalan/HDS and to administer high dose chemotherapy to the liver. The company sells its proprietary system to deliver and filter melphalan hydrochloride in Europe under the trade name, Delcath Hepatic Chemosat Delivery System for Melphalan Chemosat. Delcath is headquartered in New York, the US.


Delcath Systems Inc Key Recent Developments


Jul 29,2019: Delcath enhances Board of Directors With appointment of commercial leader, John R. Sylvester

Nov 13,2018: Delcath announces third quarter fiscal 2018 financial results

Oct 15,2018: Delcath expands rollout of registration trial in metastatic ocular melanoma

Aug 15,2018: Delcath announces second quarter fiscal 2018 financial results

May 10,2018: Delcath Announces First Quarter 2018 Financial Results


Key benefits of buying this profile include:


You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.


Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.


Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.


Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.


Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.


Note: Some sections may be missing if data is unavailable for the company

Original Article: Delcath Systems Inc DCTH Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $125

NEXT ARTICLE

More From BioPortfolio on "Delcath Systems Inc DCTH Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $125"

Quick Search

Relevant Topics

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Drug Delivery
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...